Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (637)	2/6/1998 11:18:00 AM
From: David Cathcart	Read Replies (1) \| Respond to of 1826

Peter, On December 4th I posted information from a presentation given by Chuck Blitzer that morning. He stated that the current MGI 114 dose was 14.15 mg/m^2, and that it would likely go up to one more level (approximately 18 mg/m^2) before they move to phase II. Among the handouts was a chart listing the history of the dose levels as follows: MGI 114 - Current Phase I Study Dose No. of No. of mg/m^2 Patients Courses 1.0 3 7 1.5 1 2 2.25 1 2 3.38 (nausea/vomiting) 3 7 4.5 (phlebitis) 3 5 6.0 1 1 8.04 (mucositis, fatique) 7 15 10.64 2 6 14.15 7 9 Total 28 54 Increased creatinine, metabolic acididosis, & thrombocytopenia (in renally compromised patients) 5 minute infusion over 5 days every 28 days My earlier post that you referred to was information that was taken from a broker that had spoken to the company. The above information is straight from MGI Pharma. Based on that I would say that the information on the link from RDB referred to the earlier 6.0 mg/m^2 course. David